# A041703 (inotuzumab ozogamicin): what clinicians are saying

> 133 statements from 26 sources (5 videos, 18 posts, 3 papers), 63 of them from 10 confirmed clinicians, each linked to its source. Commentary checked Nov 9, 2026.

## Report

- Trial: A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
- NCT ID: NCT03739814
- Registry: https://clinicaltrials.gov/study/NCT03739814
- Sponsor: National Cancer Institute (NCI)
- Phase: Phase 2
- Status: Recruiting
- Drugs tested: inotuzumab ozogamicin plus blinatumomab; inotuzumab ozogamicin plus blinatumomab plus ponatinib
- Indication: CD22-positive B-lineage acute lymphoblastic leukemia
- Version: v1.0.0, edition 1
- Accepted: 2026-11-09 UTC
- Last checked: 2026-11-09 UTC
- Release hash: f057d52c65b5c898ac2e3bf3c94f918e173c0c25748d9f14df63436798853cc3

## Counts

- Commentary sources screened: 58
- Sources cited by verified statements: 26
- Verified statements: 133
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 63
- Findings: 6
- Named people in screened sources (unnamed speakers and accounts not counted): 17
- Speakers cited: 16
- Cited speakers with a verified identity: 12
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 10
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 10
- By role and specialty (the abstract's specialty counts):
  - 5 physician, Medical oncology
  - 3 physician, Hematology and oncology
  - 2 physician, specialty not confirmed
- Organisational or shared accounts (not counted as people): 4

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

One physician regards A041703 as a potential treatment standard because of reduced chemotherapy-related toxicity, while noting shorter follow-up. A hematologist-oncologist described in the sources as the trial’s presenter, a principal investigator and a results author considers remissions apparently durable with longer follow-up, but seeks randomized evidence before ruling out added benefit from chemotherapy. Hoped-for relevance to younger patients remains unproven.

## Question clinicians left open

What do clinicians need to see on event-free survival, overall survival and non-relapse mortality from a randomized comparison of A041703’s inotuzumab–blinatumomab sequence with versus without systemic chemotherapy in adults aged 60 or older with newly diagnosed Ph-negative, CD22-positive B-ALL?

From finding F1 (17 statements from 2 speakers in 8 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Speakers favor a chemotherapy-free option, while one presenter leaves chemotherapy’s added value unresolved
  - 17 statements from 2 speakers in 8 sources, 1 of them a podcast or video.
- F2. Clinicians cite late toxicity when weighing chemotherapy avoidance, especially after age 70
  - 8 statements from 4 speakers in 5 sources, 2 of them podcasts or videos.
- F3. One X account favors inotuzumab induction but questions high-risk efficacy and CNS protection
  - 13 statements from 4 speakers in 4 sources, 2 of them podcasts or videos.
- F4. One X account highlights MRD and CD22 as prognostic warning signs
  - 8 statements from 2 speakers in 4 sources, 1 of them a podcast or video.
- F5. One speaker welcomes POMP omission and favors individualized surveillance
  - 8 statements from 1 speaker in 1 source, a podcast or video.
- F6. In a webinar, unattributed remarks value shorter treatment but question continuous-infusion access
  - 11 statements from 3 speakers in 3 sources, 1 of them a podcast or video.

The full report also has 3 findings about other patients, lines of treatment or settings, after these trial findings under “Beyond the trial population”. They are not counted or listed on this page.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 17 | 15 | 8 | 2 | 3 |
| F2 | 8 | 10 | 5 | 4 | 3 |
| F3 | 13 | 11 | 4 | 4 | 3 |
| F4 | 8 | 8 | 4 | 2 | 3 |
| F5 | 8 | 3 | 1 | 1 | 4 |
| F6 | 11 | 8 | 3 | 3 | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 7 | 2 | 1 | 3 | 4 | 18 | 3 | 6 posts and articles, 1 podcast or video, 1 publication |
| F2 | 4 | 0 | 2 | 1 | 1 | 11 | 1 | 2 posts and articles, 2 podcasts and video, 1 publication |
| F3 | 5 | 3 | 0 | 2 | 3 | 13 | 0 | 1 post or article, 2 podcasts and video, 1 publication |
| F4 | 5 | 0 | 0 | 1 | 2 | 8 | 2 | 2 posts and articles, 1 podcast or video, 1 publication |
| F5 | 5 | 1 | 1 | 0 | 1 | 8 | 0 | 1 podcast or video |
| F6 | 4 | 1 | 2 | 2 | 2 | 11 | 6 | 2 posts and articles, 1 podcast or video |

### Trial dimensions

- Primary endpoint: Event-free survival: F1 (5 shared claims), F3 (1 shared claims), F4 (1 shared claims), F5 (1 shared claims), F6 (2 shared claims)
- Primary endpoint: Completion of protocol treatment (cohort 3): no finding draws on it directly
- Secondary endpoints: F1 (6 shared claims), F3 (1 shared claims), F4 (4 shared claims), F5 (2 shared claims), F6 (2 shared claims)
- Population and setting: F1 (4 shared claims), F6 (1 shared claims)
- The comparison: F1 (6 shared claims), F2 (3 shared claims), F3 (4 shared claims), F6 (1 shared claims)
- Safety and tolerability: F1 (3 shared claims), F2 (7 shared claims), F3 (2 shared claims)
- Design and conduct: F1 (1 shared claims)

## Abbreviations

- CNS: central nervous system
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- MRD: measurable residual disease
- NPI: National Provider Identifier, the US registry number for clinicians

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 133 | Paid |
| Who said each statement, with each cited speaker's role and what confirmed it (NPI registry or staff page) | 16 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 26 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
| Verified speaker IDs as data (NPI, social and scholarly IDs) | 12 | 12-month plan add-on |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 10 of the 16 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key. The verified speaker identities add-on, sold with 12-month plans, adds each verified person's IDs as data (the NPI number, X, Bluesky and LinkedIn accounts, ORCID and institutional pages), so your team can check each attribution itself. It is for checking attribution inside your organization, and it does not unlock who said what. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

13 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Event-free survival | discussed | 14 | 10 |
| Primary endpoint: Completion of protocol treatment (cohort 3) | no commentary found | 0 | 0 |
| Secondary endpoints | discussed | 18 | 11 |
| Population and setting | discussed | 15 | 8 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 20 | 8 |
| Safety and tolerability | discussed | 13 | 9 |
| Design and conduct | discussed | 9 | 3 |
| MRD, antigen expression and relapse reassessment | discussed | 7 | 4 |
| Maintenance omission and post-treatment surveillance | discussed | 9 | 2 |
| Administration burden, access and patient support | discussed | 11 | 3 |
| Treatment positioning and perceived significance | discussed | 19 | 16 |
| Future evidence generation, representation and broader applicability | discussed | 6 | 2 |
| Separate phase Ib/II inotuzumab–blinatumomab–steroid study in patients over 70 | discussed | 4 | 1 |
| Broader response-adapted escalation, cellular therapy and transplant decisions | discussed | 10 | 4 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 50 statements · 38%** (from 5 videos · about 10 per source) | | | |
| YouTube | 47 | 4 | 4 |
| X videos | 3 | 1 | 1 |
| **Posts · 46 statements · 34%** (from 18 posts · about 3 per source) | | | |
| X threads | 41 | 15 | 45 |
| Bluesky threads | 5 | 3 | 8 |
| **Primary sources · 37 statements · 28%** (cited for context, not screened · from 3 sources · about 12 per source) | | | |
| Publications (primary source, cited for context) | 37 | 3 | not screened |

- Screened window: 2018-12-03 to 2026-11-06
- Cited window: 2023-10-22 to 2026-11-06
- Retrieved: 2026-11-09

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
- Registry: NCT03739814 (https://clinicaltrials.gov/study/NCT03739814)
- Study IDs: NCI-2018-02484 · A041703 (Alliance for Clinical Trials in Oncology; CTEP) · U10CA180821
- Sponsor: National Cancer Institute (NCI)
- Design: Phase 2 · interventional, non randomized, parallel, phase2
- Status: Recruiting
- Enrollment: 84 (estimated)
- Start: 2019-05-08 (actual)
- Primary completion: 2027-02-01 (estimated)
- Primary endpoint: Event-free survival (At 1 year)
- Primary endpoint: Completion of protocol treatment (cohort 3) (Up to 10 years)
- Intervention: Biospecimen Collection (procedure)
- Intervention: Blinatumomab (biological)
- Intervention: Bone Marrow Aspiration (procedure)
- Intervention: Bone Marrow Biopsy (procedure)
- Intervention: Inotuzumab Ozogamicin (biological)
- Intervention: Lumbar Puncture (procedure)
- Intervention: Ponatinib (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on post-treatment MRD surveillance intervals for older adults who completed therapy with MRD negativity during treatment.
- 34 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 30 sources about other trials or topics are not included.
- This is an account of the sources reviewed for this edition, not all HCPs or all public discussion. Comments that do not name the trial or use different terminology or transcription may be missing.
- The clinical discussion overwhelmingly concerns Cohort 1 in older patients with newly diagnosed Ph-negative, CD22-positive B-ALL. It cannot support equivalent conclusions for relapsed/refractory disease or the other cohorts.
- The published study is small and nonrandomized. Historical and cross-study comparisons involve different populations, time periods, regimens and follow-up, so they cannot establish chemotherapy’s incremental benefit or comparative safety.
- The publication reports median follow-up of 30 months; the extended presentation reports 45 months. These analyses and earlier summaries should not be treated as one contemporaneous dataset.
- MRD associations are limited by sample availability, detectable ASO-PCR clones and assay sensitivity. They do not establish a treatment-selection effect or a validated escalation algorithm.
- Some reported numbers and disease labels differ between sources. The report preserves those differences as attributed statements rather than silently correcting them.
- Some remarks cannot be assigned to a named participant, and clinical roles are not established for every named account or speaker. Trial-involvement descriptions come from the sources themselves, not independent confirmation.
- No separate protocol was available. Lack of commentary on an indexed topic means no substantive discussion was found in the material reviewed, not that clinicians have no concerns about it.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-09 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-09 UTC. No changes.

## Offer

- Size: Focused · 133 verified statements · 63 from 10 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Optional verified speaker identities (12-month updates only, product updates-12-identities; speakers are named and described in every report): the NPI and other verified IDs, to check that each statement is attributed to the right person, at $15 per identity-verified person in the edition at purchase (12 now), at most $750; people verified later in the term at no charge. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/a041703-nct03739814
- Agents: POST https://www.erudio.com/api/orders with {"report": "a041703-nct03739814", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=a041703-nct03739814

## Cite

Erudio Health. A041703 (NCT03739814): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 9, 2026. https://www.erudio.com/reports/a041703-nct03739814

## Machine access

- JSON: https://www.erudio.com/reports/a041703-nct03739814.json
- Markdown: https://www.erudio.com/reports/a041703-nct03739814.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/a041703-nct03739814/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "a041703-nct03739814"}`